The growth in biotechnology and biological sciences present new opportunities for investment, mergers and acquisitions.
Underpinning the headline financial offering is the technology itself. In a rapidly-changing scientific and regulatory environment there is a need to understand the realistic and realisable value of the asset.
Queen’s House Consulting can provide technical services to M&A and investment professionals, offering critique of scientific data and development prospects for biotech and biological therapeutics, from the laboratory bench through to market launch:
-
Independent assessment of blue sky discovery potential;
-
Technical SWOT analysis of proposed and next-phase bio/tech start-up businesses;
-
Gap analysis to add value to the bio/tech asset;
-
Identification of realistic timelines and resources to achieve technical gateway milestones.
If you are engaged in the financing, negotiation or partnering of investment, mergers and acquisitions in the biological/biotechnology sector, please contact Queen’s House Consulting to discuss your specific requirements.
Google+